Phillips-Medisize, a Molex company, announced the opening of a global innovation and development (GID) center near Copenhagen to support long-term growth plans for its advanced injection, wearable devices and connected-health technologies.
The new center will enable the company to accelerate the creation of drug-delivery devices for its global customer base while providing an easily accessible hub for its European customers. Its location also offers access to drug-delivery and connectivity resources that complement existing Phillips-Medisize European centers in Struer, Denmark and Cambridge, UK.
By establishing a presence near Copenhagen, Phillips-Medisize is in the middle of the Medicon Valley cluster, close to top universities, hospitals and global R&D-based pharmaceutical and medical device companies. This Scandinavian region is a natural entry point into Europe and is home to innovators exploring large unmet medical needs in areas such as oncology, diabetes and personalized medicine, according to Phillips-Medisize.
“The opening of our new Copenhagen GID center represents an exciting opportunity to expand our global footprint by supporting overall growth with closer proximity to current European clients, fortifying our business development efforts and attracting top talent in the region to join our growing team,” said company president & CEO Matt Jennings in a news release.
Phillips-Medisize’s new GID center is in Teknikerbyen, Vium, in the greater Copenhagen area. A leadership team is in place and the company is recruiting pharma and medical device experts in project management, quality assurance, regulatory affairs and engineering development across mechanical, software and electronics. The first hiring phase will include 30 employees, expandable to a 100-person workforce.
Phillips-Medisize also operates GID sites in Europe, North American and Asia, most recently opening an office in Bangalore, India.
